Point-of-Care Assay for Type 1 Diabetes Diagnosis and Prognostication
Point-of-Care Assay for Type 1 Diabetes Diagnosis and Prognostication
批准号:
10721535
负责人:
Eric Ervin
金额:
$28.45万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-09-01 至 2024-08-31
关键词:
AffectAntibodiesAntigensAutoantibodiesAutoimmune DiseasesAutoimmunityBeta CellBindingBiological AssayBiological MarkersBiological SciencesBiosensorBloodBlood specimenBuffersC-PeptideCharacteristicsChargeChemistryChildChronic DiseaseClinical TrialsCollaborationsDependenceDetectionDevelopmentDiabetes autoantibodiesDiabetic KetoacidosisDiagnosisDiagnosticDiseaseEarly DiagnosisElectrolytesElectronicsElementsEmergency department visitEnzyme-Linked Immunosorbent AssayEvaluationExcisionFiltrationFingersFoundationsGeneral PopulationGlutamate DecarboxylaseGoalsHealthImmobilizationImmune systemImmunoassayIndividualInsulinInsulin-Dependent Diabetes MellitusIonsIslets of LangerhansLifeLigandsLow PrevalenceMeasurementMeasuresMedicalMicrofluidicsMolecularNanotechnologyOutcomePancreasPathologyPatientsPerformancePersonsPhasePlasmaPopulationPrognosisProteinsPublic HealthReaderSamplingSensitivity and SpecificityShapesSideSignal TransductionSmall Business Innovation Research GrantSurfaceSymptomsTechnologyTestingTubeUnited StatesUniversitiesUtahVial deviceWhole Bloodbiomarker panelbiomarker validationclinical developmentclinically relevantcostdesigndetection assaydetection limitearly detection biomarkersearly screeninghospitalization ratesimprovedinsulin secretionisletislet cell antibodylaboratory facilitymid-career facultynanoporenovel therapeuticspoint of carepoint of care testingprognosticprognostic valueprognosticationprogramsprototyperapid detectionresponsesample collectionscreeningscreening programsensor technologysignal processingsocialsuccesstoolvoltagezinc-binding protein
中文摘要
项目总结
英文摘要
Project Summary
Type 1 diabetes (T1D) affects ~1.5 million people in the US and is the second most common chronic illness in
children. T1D occurs as the result of a mistaken attack by the immune system on the pancreas. Autoantibodies
to pancreatic islet antigens, a byproduct of T1D autoimmunity, are well-validated biomarkers for T1D. They are
present in blood long before the development of clinical T1D symptoms, and serve as ideal biomarkers for the
early diagnosis of T1D. Large clinical trials have proven that screening children for T1D autoantibodies is an
effective way to reduce life-threatening episodes of ketoacidosis. And, these patients can be treated with a new
drug (teplizumab), which delays the onset of insulin dependence by an average of 2.8 years. These recent
developments demonstrate the obvious medical and social benefits of population-level screening of children for
T1D autoantibodies, but this worthy goal would require many millions of T1D autoantibody tests to be performed
each year in the US alone. This feat is out of reach with current testing technology, which is slow, expensive,
and requires centralized laboratory facilities. The only possible solution to this problem is a point-of-care T1D
autoantibody test, yet point-of-care tests to date have lacked the necessary analytical performance.
In this Phase I project, Electronic BioSciences, Inc. will develop a T1D assay, based on the latest developments
in nanopore technology, to rapidly detect a panel of the most clinically relevant T1D autoantibodies in a point-of-
care format. A key aspect of the FiND technology is its capacity to be highly multiplexed, which will allow new
T1D autoantibody biomarkers to be added to the panel as they are discovered and validated, which will further
improve the diagnostic and prognostic capability of the test. The proposed low cost, high performance, T1D test
is the ideal solution for population-level T1D screening.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Sequencing the Mono-Methylated Derivatives of Cytidine
-
批准号:10581093
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2023
-
负责人:Eric Ervin
-
依托单位:
Nanopores for Processing Proteins
-
批准号:10645984
-
项目类别:
-
资助金额:$40.73万
-
财政年份:2023
-
负责人:Eric Ervin
-
依托单位:
Nanoscale Tools for Inosine Sequencing
-
批准号:10437956
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2022
-
负责人:Eric Ervin
-
依托单位:
Nanoscale Tools for Inosine Sequencing
-
批准号:10651806
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2022
-
负责人:Eric Ervin
-
依托单位:
Comprehensive Botulinum Characterization via the Bilayer Nanowell Integrated Assay
-
批准号:10480376
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2022
-
负责人:Eric Ervin
-
依托单位:
Exonuclease Based Microsatellite Sequencing
-
批准号:10481241
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2022
-
负责人:Eric Ervin
-
依托单位:
Long-lived Platform Development for Exonuclease-Based Sequencing
-
批准号:10322603
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2021
-
负责人:Eric Ervin
-
依托单位:
Exonuclease Epigenetic Sequencing
-
批准号:10009454
-
项目类别:
-
资助金额:$89.7万
-
财政年份:2018
-
负责人:Eric Ervin
-
依托单位:
Nanopore Enabled Exonuclease Sequencing
-
批准号:9171771
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2016
-
负责人:Eric Ervin
-
依托单位:
Bilayer Nanopore Integrated Assay
-
批准号:8831199
-
项目类别:
-
资助金额:$17.97万
-
财政年份:2015
-
负责人:Eric Ervin
-
依托单位:
Optimizing Nanopore Protein Interactions
-
批准号:8892399
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2015
-
负责人:Eric Ervin
-
依托单位:
Identification and Quantification of Sequence Specific RNA Modifications via the Alpha-Hemolysin Latch Zone
-
批准号:8841921
-
项目类别:
-
资助金额:$21.57万
-
财政年份:2014
-
负责人:Eric Ervin
-
依托单位:
Encapsulated Lipid Bilayer Based Assay for Assessing Botulinum Neurotoxin Potency
-
批准号:8251686
-
项目类别:
-
资助金额:$18.49万
-
财政年份:2012
-
负责人:Eric Ervin
-
依托单位:
Nanopore Based Methods for Enantiomer Differentiation
-
批准号:8001793
-
项目类别:
-
资助金额:$16.68万
-
财政年份:2010
-
负责人:Eric Ervin
-
依托单位:
海外基金